You are here: Industry Insights > NATCO

News List

NATCO launches Rivaroxaban¸ anticoagulant medication in India expresspharma
December 18, 2020
Natco Pharma announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under the brand name of Xarelto, in the Indian market.
Panacea inks pact with Natco, Breckenridge for cancer drug expressbpd
August 28, 2018
Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec’s Baddi facility
Natco Pharma invests Rs 7.5 cr in PACE Hospital expressbpd
November 07, 2017
“Natco Pharma has executed definitive agreement and subscribed to 7.5 per cent of the paid-up equity share capital of OMRV Hospitals,” it said in a BSE filing.
Natco gets US FDA nod to market renal disease drug expressbpd
August 15, 2017
The product, as the first generic, will be launched shortly in the US market
Natco Pharma receives EIR from US FDA financialexpress
July 21, 2017
The inspection was conducted at Natco Pharma’s Kothur facility in Telangana
NATCO receives FDA approval for Vidaza for USA market biospectrumasia
June 29, 2017
Vidaza is anti-cancer chemotherapy drug that is used for myelodysplastic syndrome (MDS)
Natco plans to launch 8-10 branded formulations this year expressbpd
June 07, 2017
Natco Pharma plans to launch around 8-10 new products in domestic branded formulations segment during the current year as it aims to grow over 20 per cent year-on-year during the period.

Previous page 1 2 Next page